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K-Ras must localize to the plasmamembrane and be arrayed in nanoclusters for biological activity. We show here that K-Ras is a
substrate for cyclic GMP-dependent protein kinases (PKGs). In intact cells, activated PKG2 selectively colocalizes with K-Ras on
the plasmamembrane and phosphorylates K-Ras at Ser181 in the C-terminal polybasic domain. K-Ras phosphorylation by
PKG2 is triggered by activation of AMP-activated protein kinase (AMPK) and requires endothelial nitric oxide synthase and sol-
uble guanylyl cyclase. Phosphorylated K-Ras reorganizes into distinct nanoclusters that retune the signal output. Phosphoryla-
tion acutely enhances K-Ras plasmamembrane affinity, but phosphorylated K-Ras is progressively lost from the plasmamem-
brane via endocytic recycling. Concordantly, chronic pharmacological activation of AMPK¡ PKG2 signaling with
mitochondrial inhibitors, nitric oxide, or sildenafil inhibits proliferation of K-Ras-positive non-small cell lung cancer cells. The
study shows that K-Ras is a target of a metabolic stress-signaling pathway that can be leveraged to inhibit oncogenic K-Ras
function.
Ras proteins are small GTPases that regulate important cellularsignaling cascades to control cell growth, proliferation, and
differentiation (1). The three Ras isoforms, H-, N-, and K-Ras4B
(here, K-Ras), are ubiquitously expressed inmammalian cells. Ras
proteins must be localized to the inner leaflet of the plasmamem-
brane (PM) by a C-terminal membrane anchor for biological ac-
tivity. In the case of K-Ras, the anchor comprises a posttransla-
tionally attached C-terminal cysteine farnesyl-methyl ester
operating in concert with a polybasic motif of 6 lysine residues (2,
3). Electrostatic interactions between the K-Ras C-terminal poly-
basic domain and the negatively charged inner leaflet of the PM
providemembrane affinity (2, 4–9). Maintenance of K-Ras on the
PM also requires the chaperone protein PDE (10). Cytosolic
PDE binds K-Ras released from the PM as a result of endocytosis
and unloads K-Ras in the perinuclear region in response to Arl2/3
binding, whence K-Ras translocates to the recycling endosome
(RE) for redelivery to the PM by vesicular transport (11). Ras
proteins on the PM are spatially organized into nanodomains,
called nanoclusters, that are required for high-fidelity signal trans-
duction by the Ras/mitogen-activated protein kinase (MAPK)
pathway (12–14). Ras GTP nanoclusters contain6 to 7 Ras pro-
teins, are 20 nm in diameter, and are exclusive platforms for
Raf recruitment and MEK/extracellular signal-regulated kinase
(ERK) activation. Perturbation of the spatiotemporal dynamics of
Ras nanoclustering disrupts cellular signaling (15, 16).
We have used a high-content cell-based screen (HCS) to iden-
tify multiple chemical compounds that mislocalize K-Ras from
the PM and abrogate K-Ras signal transmission (17, 18). One
group of compounds disrupts the cellular phosphatidylserine
(PtdSer) distribution or PtdSer levels with a consequent reduction
in the PtdSer content of the inner leaflet of the PM (18–21). Since
PtdSer is an anionic phospholipid that provides much of the elec-
trostatic surface potential to the inner PM, a reduced PtdSer PM
content leads to K-Ras dissociation. A second group of com-
pounds includes a diverse set of mitochondrial inhibitors (22–24)
that all triggered activation of the master metabolic kinase, AMP-
activated protein kinase (AMPK). In dissecting the molecular
mechanism, we identified cyclic GMP (cGMP)-dependent pro-
tein kinases (PKGs) regulated by nitric oxide (NO) signaling to be
novel K-Ras kinases. We show that PKGs directly phosphorylate
K-Ras at Ser181 to regulate multiple aspects of K-Ras–PM inter-
actions. Our data further show that pharmacological activators of
this signaling pathway can inhibit proliferation of K-Ras-positive
non-small cell lung cancer (NSCLC) cells.
MATERIALS AND METHODS
Cell culture and reagents. Madin-Darby canine kidney (MDCK) and
baby hamster kidney (BHK) cells were maintained in Dulbecco’s modi-
fied Eagle medium (Gibco) supplemented with 2 mM L-glutamine and
10% fetal bovine serum (FBS) or 10% donor calf serum, respectively.
A549 cells were maintained in Ham’s F-12K medium (ATCC) supple-
mented with 10% FBS with 2 mM L-glutamine. H358, H441, and H2122
cells were maintained in RPMI 1640 (ATCC) supplemented with 10%
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FBS and 2 mM L-glutamine. All cell lines were grown at 37°C in 5% CO2.
Antibodies against phospho-p42/44 mitogen-activated protein kinase
(MAPK; ERK1/2; T202/T204; catalog number 4370), phospho-Akt
(Ser473; catalog number 4060), phospho-endothelial nitric oxide syn-
thase (phospho-eNOS; S1177; catalog number 9570), phospho-AMPK
(T172; catalog number 2535), phospho-vasodilator-stimulated phospho-
protein (phospho-VASP; S239; catalog number 3114), total VASP (cata-
log number 3132), phospho-CRaf (S338; catalog number 9427), and
phospho-MARCKS (S152/156; catalog number 2741) were fromCell Sig-
naling Technology. Antiactin (catalog number A2228) and antiphospho-
serine (catalog number ab9332) antibodies were obtained from Sigma-
Aldrich and Abcam, respectively. Neoantimycin and oligomycin A were
obtained from BioAustralis (Australia). 8-Br-cGMP (catalog number
BML-CN205), L-NG-nitroarginine methyl ester (L-NAME; catalog num-
ber ALX-105-003), and diethylamine nitric oxide (DEA-NO; catalog
number ALX-430-034)were fromEnzo Life Sciences.Metformin (catalog
number D150959) was from Sigma-Aldrich, and aminoimidazole-4-car-
boxamide riboside (AICAR; catalog number 9944) was from Cell Signal-
ing Technology. Sildenafil citrate (catalog number RSC01) was obtained
from Biotang Inc.
In vitro phosphorylation.All glutathione S-transferase (GST)-tagged
K-Ras proteins and GST-tagged RhoA proteins were produced in Esche-
richia coli BL21 cells. Overnight cultures were diluted 1:10 and grown for
1 h at 37°C, protein expression was induced by adding 1 mM isopropyl-
1-thio--D-galactopyranoside, and cultures were grown for an additional
3 h at 37°C. Bacteria were harvested by centrifugation, the pellet was
resuspended in bacterial lysis buffer (50 mM Tris-HCl [pH 7.4], 200 mM
NaCl, 5 mM MgCl2), and the bacteria were lysed by sonication. Lysates
were cleared by centrifugation at 16,000 g for 10min, and proteins were
isolated by incubationwith glutathione-Sepharose beads (GEHealthcare)
for 1 h at 4°C. The beads were washed in bacterial lysis buffer, and the
proteins bound to the beads were quantified by the Bradford assay. For in
vitro kinase reactions, beads containing 3 g wild-type or mutant K-
Ras or RhoA were incubated with 100 ng PKG in kinase reaction buffer
(30 mM HEPES [pH 7.0], 10 mM MgCl2, 10 mM, -glycerol phos-
phate, 1 mM dithiothreitol, 5 M 8-chlorophenylthio-cGMP, 10 Ci
[	-32PO4]ATP) for 5 min at 30°C. After 5 min, cold ATP was added to 5
M and the reaction mixture was incubated at 30°C for an additional 5
min. Reactions were stopped by washing the beads in phosphate-buffered
saline (PBS) containing 0.1% NP-40. The beads were boiled in SDS sam-
ple buffer, and phosphorylation was analyzed by SDS-PAGE/autoradiog-
raphy. Equal loading of the GST-tagged proteins was confirmed byWest-
ern blotting with anti-GST antibody (Santa Cruz Biotechnology).
Detecting K-Ras phosphorylation in vivo. MDCK cells stably ex-
pressing monomeric enhanced green fluorescent protein (mGFP)-tagged
K-Ras (mGFP–K-Ras) or phosphosite mutants were treated with PKG
activators when they were at a confluence of70% on a 10-cm dish. Cells
were harvested with 1 ml of binding buffer (50 mM Tris [pH 7.5], 1%
Triton X-100, 5 mM MgCl2, 25 mM NaF, 75 mM NaCl, 5 mM Na-pyro-
phosphate, 20 mM -glycerophosphate, 100 M Na3VO4, 1 mM dithio-
threitol, leupeptin [3.33 g/ml], aprotinin [0.33 g/ml]). Cell debris was
cleared by centrifugation, and the supernatant was incubated with 10 ml
binding buffer plus 15 l GFP-Trap beads (50% slurry; catalog number
GFA-0050; Chromotek) overnight at 4°C. The beads were washed 3 times
with 1ml binding buffer and then incubated in 80l 2 sample buffer for
5 min at 95°C. Protein samples were resolved on 8% SDS-polyacrylamide
gels and transferred to a polyvinylidene difluoride (PDVF) membrane
using a semidry transfer apparatus. The PVDFmembrane was then incu-
bated with 4% paraformaldehyde and 0.01% glutaraldehyde for 30min at
room temperature (RT) to increase the immunogenicity of the phospho-
proteins (25), washed 3 times with Tris-buffered saline with 0.1% Tween
20 (TBS-T), and blocked with 10% bovine serum albumin in TBS-T for 2
h at RT. The membrane was incubated with antiphosphoserine antibody
(1:1,000) overnight at 4°C. The signal was detected by enhanced chemi-
luminescence as described below. The extra fixation of the PVDF mem-
brane used in this protocol, including the ratio of paraformaldehyde to
glutaraldehyde, and the blocking time were optimized to maximize an-
tiphosphoserine immunodetection.
Electron microscopy (EM) and spatial mapping. Plasma membrane
sheets were prepared and fixed as previously described (18, 26, 27). For
univariate analysis, plasmamembrane sheets were labeled with anti-green
fluorescent protein (anti-GFP) antibody conjugated to 4.5-nm gold par-
ticles. For bivariate analysis, plasma membrane sheets were labeled with
anti-monomeric enhanced red fluorescent protein (anti-mRFP) antibody
conjugated to 2-nm gold particles and anti-GFP antibody conjugated to
6-nm gold particles. Digital images of the immunogold-labeled plasma
membrane sheets were taken in a transmission electron microscope. In-
tact 1-m2 areas of the plasma membrane sheet were identified using
ImageJ software, and the (x, y) coordinates of the gold particles were
determined (26, 27). K-functions (28) were calculated and standardized
on the 99% or 95% confidence interval (CI) for univariate or bivariate
functions, respectively (26, 27, 29). In the case of univariate functions, a
value of L(r) 
 r greater than the CI indicates significant clustering, and
themaximum value of the function (Lmax) estimates the extent of cluster-
ing. Differences between replicated point patterns were analyzed by con-
structing bootstrap tests as described previously (14, 29), and the statistical
significance against the results obtained with 1,000 bootstrap samples was
evaluated. In the case of bivariate functions, under the null hypothesis that
there is no spatial interaction between the two populations of gold particles,
Lbiv(r)
 r has an expected value of 0 for all values of r. As for L(r)
 r, values
of Lbiv(r) 
 r greater than the CI indicate significant coclustering of the
two populations of gold. For a simple summary statistic, the Lbiv(r) 
 r
function is standardized (Std) on the 95% confidence interval and inte-
grated over a fixed range to derive the LBI parameter, as follows:
LBI 110
10
Std Lbiv(r) r · dr
LBI has an expected value of 100 for proteins that do not cocluster. Dif-
ferences between LBI values are evaluated in bootstrap tests on the actual
Lbiv(r)
 r function.
Western blotting. Cells were washed in cold PBS and lysed in buffer
containing 50 mM Tris HCl (pH 7.5), 75 mM NaCl, 25 mM NaF, 5 mM
MgCl2, 5 mM EGTA, 1 mM dithiothreitol, 100 M Na3VO4, and 1%
NP-40 plus protease inhibitors. SDS-PAGE and immunoblotting with the
antibody specified below were performed using 20 g of each lysate. The
signalwas detected by enhanced chemiluminescence (SuperSignal; Pierce,
Thermo Fisher Scientific, Rockford, IL) and imaged using a FluorChemQ
imager (Alpha Inotech, San Leandro, CA). Quantification of intensities
was performed using FluorChemQ software.
Cell proliferation assay.Cancer cells (5,000 per well) were plated on a
96-well plate (catalog number 137101; Thermo Scientific). Twenty-four
hours later, the cells were incubated with the compounds indicated below
for 3 days. Fresh complete growth medium with the compounds was
replaced every 24 h. Cell proliferation was assayed using a CyQuant pro-
liferation assay kit (catalog number C7027; Invitrogen) according to the
manufacturer’s instructions. Plates were read using a Tecan Infinite 200
plate reader (excitation   480 nm, emission   520 nm).
siRNA-mediated PKG2 knockdown. MDCK cells (1.0  105 cells)
stably expressing mGFP-tagged K-Ras with a G12V substitution (mGFP–
K-RasG12V) were mixed with 80 nM PKG2-targeting small interfering
RNA (siRNA) [sense sequence, 5=-CUGCUUGGAAGUGGAAUACUA
(dT)(dT)-3=; antisense sequence, 5=-UAGUAUUCCACUUCCAAG
CAG(dT)(dT)-3=] (30) or a nontargeting scramble siRNA control
(catalog number D-001810-10-01; Dharmacon) and a transfection re-
agent (DharmaFECT I; Dharmacon), and themixture was plated in trip-
licate in a 6-well plate. After 48 h, the plated cells were retransfected with
80 nM siRNA. After a further 48 h, the cells were either treated with
compounds or harvested for mRNA extraction. To verify knockdown,
exon-exon boundary-spanning primers specific for canine PKG2 exons
14 and 15 and GAPDH (glyceraldehyde-3-phosphate dehydrogenase)
exons 2 and 3 were designed: for PKG2 exons 14 and 15, 5=-GACATT
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CAAATC-3=, respectively, and for GAPDH exons 2 and 3, 5=-ATTTGG
CCGTATTGGGCGC-3= and 5=-TCCTGGAAGATGGAGATGGAC-3=,
respectively.
cDNA was generated from MDCK cells stably expressing mGFP–K-
RasG12V after transfectionwith PKG2 or scrambled siRNA and amplified
by PCR, and the products were resolved by agarose gel electrophoresis and
visualized by ethidium bromide staining.
Confocal microscopy. Cells were fixed with 4% paraformaldehyde,
followed by 50 mM NH4Cl treatment to quench aldehyde groups. Cells
were imaged in a Nikon A1R confocal microscope using 60 objectives.
Statistical analysis.Prism software (version 5.0c;GraphPad Software)
was used for one-way analysis of variance (ANOVA) testing and two-
tailed t tests.
MD. Atomistic molecular dynamics (MD) simulations were per-
formed on wild-type K-Ras and the phospho-membrane-targeting motif
of K-Ras (phospho-tK) in a negatively charged bilayer following a previ-
ously described protocol (31). Briefly, a symmetric bilayer of 104 1-palmi-
toyl-2-oleoyl-sn-glycero-3-phosphocholine and 1-hexadecanoyl-2–(9Z-
octadecenoyl)-sn-glycero-3-phospho-L-serine lipids and two peptides per
leaflet was solvated by TIP3P water molecules using a simulation of a box
of 110 by 65 by 95 Å3, and charge-neutralizing sodium ions were added.
The resulting 650,000-atom systemwas energyminimized for 2,000 steps,
with lipid and protein heavy atoms being fixed. It was then equilibrated,
using a time step of 1 fs, for 200 ps, with the lipid phosphate atoms and
protein heavy atoms being harmonically restrained with a force constant
(k) of 4 kcal/mol/Å2. This was followed by four steps of 100-ps runs with
k scaled by 0.75, 0.50, 0.25, and 0. The resulting system was simulated for
1 s with a 2-fs time step, with all bonds involving hydrogens being re-
strained by SHAKE, and by the use of particle mesh Ewald electrostatics
with 12-Å and 14-Å cutoffs for nonbonded interactions and pair-list up-
dates, respectively. Constant pressure (105 Pa) and temperature (310 K)
were maintained using the Nose-Hoover Langevin piston and the Lan-
gevin thermostat methods, respectively. The force field was CHARMM27
(32) for proteins and CHARMM36 for lipids (33). Simulations were con-
ducted with the NAMD2.9 program (34) for 1 s.
RESULTS
AMPK activation triggers dissociation of K-Ras from the PM.
Among a set of compounds that displace K-RasG12V but not
H-RasG12V from the PM in an HCS (18), we found an oligomy-
cin family and a rare neoantimycin family of Streptomyces-derived
molecules and the antidiabetic drug metformin (22–24, 35) (Fig.
1A and B). All of these compounds have been reported to inhibit
various aspects of mitochondrial function (22–24, 35). Since in-
hibition of mitochondrial activity depletes cellular ATP levels and
activates AMPK (36, 37), we tested whether direct AMPK activa-
tion would also mislocalize K-RasG12V. To this end, we used a
confocal imaging assay that measures the colocalization of
mGFP–K-RasG12V with a generic endomembrane marker,
mCherry-CAAX (18). In this assay, the extent of colocalization of
mGFP–K-RasG12V andmCherry-CAAXwas quantified by use of
a Manders coefficient, which provides an estimate of the fraction
of K-Ras displaced from the PM (Fig. 1A). Figure 1 shows that the
direct AMPK activator aminoimidazole-4-carboxamide riboside
(AICAR) very effectively displaces K-RasG12V from the PM. To
explore the molecular mechanism, we first examined the cellular
distribution of PtdSer, because the PM PtdSer content is critical
for K-Ras PM binding (18–21). We analyzed the localization of
the PtdSer probe LactC2 by confocal imaging (4, 38). Oligomycin
A had no effect on the distribution of LactC2 (Fig. 1C), indicating
that AMPK-mediated K-RasG12V PM mislocalization is not a
consequence of the loss of PtdSer from the inner PM. In contrast,
K-RasG12V rendered insensitive to phosphorylation by three al-
anine substitutions at Ser171, Ser181, and Thr183 in the polybasic
domain (the K-RasG12V AAAmutant; Fig. 1C) (39) was not mis-
localized by any of the mitochondrial inhibitors (Fig. 1B). Simi-
larly, a K-RasG12V mutant with a single alanine mutation at
Ser181 (K-RasG12V S181A)was insensitive to oligomycinA,met-
formin, neoantimycin, or AICAR treatment (Fig. 1B). Taken to-
gether, these results suggest that AMPK-induced K-RasG12V
dissociation from the PM is mediated through K-Ras phosphory-
lation at Ser181.
K-Ras is a direct substrate of PKGs. Protein kinase C (PKC)
can phosphorylate K-Ras at S181 and to a lesser extent at S171 and
T183 (39) (Fig. 1D). There is, however, no clear signaling pathway
from AMPK to PKC, whereas there is such a pathway to cGMP-
dependent protein kinase (PKG). Moreover, the consensus phos-
phorylation site for PKG, -Arg-Lys-Lys-X-Ser-, where X can be
any amino acid (40), resembles the K-Ras polybasic motif (Fig.
1D).We first examined if K-Ras is a PKG substrate by performing
in vitro kinase assays with recombinant PKG1, PKG1, and
PKG2 and using RhoA, a known PKG substrate, as a positive con-
trol (41). All three PKG isoforms, when activated by cGMP, phos-
phorylated K-RasG12V (Fig. 2A) but did not phosphorylate the
K-RasG12V AAA or K-RasG12V S181A mutant, indicating that
K-Ras is a PKG substrate with Ser181 as the target phosphoryla-
tion site (Fig. 2B). We next developed an in vivo assay to measure
K-Ras phosphorylation at Ser181 by endogenous protein kinases.
MDCK cells stably expressing mGFP–K-RasG12V or mGFP–K-
RasG12VS181Awere treatedwith cell-permeant 8-Br-cGMP, and
mGFP immunoprecipitates were immunoblotted with an an-
tiphosphoserine antibody after fixation of the PVDF transfer
membranes in paraformaldehyde and glutaraldehyde (25). In this
assay, 8-Br-cGMP significantly increased the K-RasG12V but not
the K-RasG12V S181A phosphoserine content (Fig. 2D), suggest-
ing that PKG activation in vivo phosphorylates K-Ras at Ser181.
Treatment with 8-Br-cGMP dose dependently and time depend-
ently stimulated K-Ras phosphorylation (Fig. 2E and F). In the
same assay, bryostatin-1, a potent PKC activator (39), elevated the
K-RasG12V phosphoserine content to the same extent as 8-Br-
cGMP but had a minimal effect on K-RasG12V S181A (Fig. 2D).
To identify the most likely candidate K-Ras kinase among the
PKG isoforms, we used electron microscopy (EM) to spatially
map the nanoscale PMdistribution of different PKGswith respect
toK-RasG12V. Intact basal PM sheets were prepared fromMDCK
cells coexpressing mGFP-PKG1 or mGFP-PKG2 and mCherry–
K-RasG12V or mCherry-H-RasG12V. The PM sheets were cola-
beled with anti-GFP and anti-RFP antibodies conjugated directly
to 6-nmor 2-nmgold particles, respectively, and the immunogold
particle point patterns revealed by EMwere analyzed using spatial
statistics. The integrated bivariate K-function (LBI), which quan-
tifies the extent of coclustering of the 6-nmor 2-nm gold particles,
showed that under nonstimulated conditions, PKG2 but not
PKG1 coclustered with K-RasG12V and H-RasG12V on the PM
(Fig. 3A and B). After treatment with 8-Br-cGMP, the PKG2 levels
on the inner PM increased significantly (Fig. 3C and D), and this
newly recruited PKG2 selectively coclustered with K-RasG12V
(Fig. 3A and B). Concordantly, siRNA knockdown of PKG2 to-
tally abolished 8-Br-cGMP-stimulated K-Ras phosphorylation,
which was rescued by ectopic PKG2 expression (Fig. 3E to G).
Knockdown of PKG2 expression also abolished the K-Ras phos-
phorylation induced by AICAR and oligomycin (Fig. 3H). Inter-
Cho et al.
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estingly, K-Ras phosphorylation in response to bryostatin-stimu-
lated PKC activation was also partially abrogated in PKG2-
knockdown cells (Fig. 3F), suggesting that PKC, in addition to
directly phosphorylating K-Ras,may also do so indirectly by caus-
ing activation of PKG2 (39). Taking these results together, we
conclude that PKG2 selectively interacts with K-Ras on the PM
and is the major PKG isoform that phosphorylates K-Ras in re-
sponse to AMPK activation.
FIG 1 AMPK activationmislocalizes K-RasG12V from the PMas a result of C-terminal phosphorylation. (A and B)MDCK cells stably coexpressingmCherry-CAAX,
a general endomembranemarker (67), andmGFP–K-RasG12V,mGFP–K-RasG12VT171A, S181A, or S183A (AAA), ormGFP–K-RasG12V S181Awere treated with
2.6 nM oligomycin A, 5.2 nM neoantimycin, 1 mM metformin, or 1 mM AICAR for 48 h, and cells were fixed and imaged using a confocal microscope. K-Ras
mislocalization from the PM was quantified as the colocalization of mGFP–K-RasG12V and mCherry-CAAX using Manders coefficients. (A) A representative image
showing the green (mGFP) and red (mCherry) channels used to calculate theManders coefficients. (B) TheManders coefficient is shown on each representative image
ofdrug-treated cells. (C)MDCKcells stably coexpressingmCherry-CAAXandmGFP-LactC2were treatedwith2.6nMoligomycinA for48hand thenfixedand imaged
using a confocal microscope. K-Ras or LactC2 mislocalization from the PMwas quantified using Manders coefficients, as described in the legend to panel A, with the
value being shown on each image. (D) K-Ras C-terminal sequence. Amino acids in red are putative phosphorylation sites. DMSO, dimethyl sulfoxide.
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AMPK and eNOS signaling regulates K-Ras interaction with
the PM. AMPK is sensitive to the cellular AMP concentration/
ATP concentration ratio and is activated bymetabolic stresses that
inhibit ATP production or increase ATP consumption (36). Ac-
tive AMPK regulates metabolism, cell signaling, transcription,
and ion transport (36). One of the effectors involved in cell signal-
ing is endothelial nitric oxide synthase (eNOS). We therefore
tested whether AMPK-mediated K-Ras dissociation from the PM
is a consequence of enhanced NO production (Fig. 4A). Both
DEA-NO, which is an NO donor, and oligomycin A triggered
K-Ras PM dissociation, which was blocked if cells were coincu-
bated with L-NAME, an NOS inhibitor (Fig. 4B). NO activates
soluble guanylyl cyclase (sGC) to produce cGMP. An alternative
mechanism to increase cGMP levels is to inhibit PDE5, which
hydrolyzes cGMP. Concordantly, sildenafil, a PDE5 inhibitor,
triggered K-Ras PM dissociation. The effects of sildenafil (and
8-Br-cGMP) were not blocked by L-NAME, which inhibits prox-
imally in the signaling pathway (Fig. 4B). Activation of AMPK and
eNOS by oligomycin A, AICAR, and metformin followed the
same time course as K-Ras PMdissociation (Fig. 5A and B). How-
ever, none of these compounds stimulated phosphorylation of
MARCKS, a PKC substrate, suggesting that AMPK-mediated K-
Ras PM dissociation is PKC independent (Fig. 5A and B). To-
gether these pharmacological data are fully consistent with the
AMPK¡ eNOS¡ PKG signaling pathway regulating K-Ras PM
interactions. One caveat here, however, is that while we have
shown that the endogenous PKG2 signaling pathway efficiently
phosphorylates ectopically expressed GFP–K-Ras, we cannot for-
mally evaluate the phosphorylation of endogenous K-Ras due to
the limitation of available reagents.
K-Ras phosphorylation regulates spatial organization and
PM interaction. K-Ras phosphorylated on S181 in response to
PKC activation laterally segregates on the PM away from non-
phosphorylated K-Ras (42). We observed a similar lateral re-
organization in response to PKG activation. Intact basal PM
sheets from 8-Br-cGMP-treated MDCK cells coexpressing
mGFP–K-RasG12V S181D, a phosphomimetic mutant (39, 42),
and mCherry–K-RasG12V were analyzed using EM and inte-
grated bivariate K-functions (LBI values.) These data show that
8-Br-cGMP drives coclustering of K-RasG12V with K-RasG12V
S181D (Fig. 6A), with the dose-response curve being similar to
that for K-Ras phosphorylation measured by Western blotting
(Fig. 2F). In control experiments, 8-Br-cGMP treatment did
not stimulate coclustering of mRFP–K-RasG12V S181A with
mGFP–K-RasG12V S181D (Fig. 6A). PKG-mediated phosphor-
ylation also increased the pair correlation function [g(r)] of the
K-Ras spatial distribution, indicating that phosphorylated K-Ras
is more tightly packed in nanoclusters than nonphosphorylated
FIG 2 K-Ras is a substrate for cGMP-activated protein kinases. (A) Recombinant GST–K-Ras was incubated in vitrowith purified PKG1, PKG1, or PKG2 and
[	-32PO4]ATP. Phosphate incorporation was analyzed by autoradiography (Autorad) (top), and equal loading was determined by anti-GST immunoblotting
(bottom). (B and C) In vitro kinase experiments as described in the legend to panel A but including recombinant GST–K-RasG12V with the S181A and AAA
(AAA S171A, S181A, T183A) mutations (B) or recombinant GST-tagged RhoA (C). (D) MDCK cells stably expressing mGFP–K-RasG12V (wild type [WT])
or mGFP–K-RasG12V S181A (S181A) were treated with 1 M bryostatin-1 (BR) for 5 min or 500 M 8-Br-cGMP (cGMP) for 15 min. mGFP–K-Ras proteins
were immunopurified and immunoblotted with an antiphosphoserine (pSer) antibody after fixation in 4% paraformaldehyde and 0.01% glutaraldehyde. The
membranes were stripped and reblotted with an anti-GFP antibody. The graph shows the mean phospho-K-Ras levels  SEM from three independent
experiments, with representative blots being shown. Significant differences between control (CTL; vehicle-treated) and drug-treated cells were assessed using
one-way ANOVA tests (**, P 0.01; N.S., not significant). (E and F) MDCK cells stably expressing mGFP–K-RasG12V were treated with 500 M 8-Br-cGMP
for the indicated times (E) or the indicated concentrations for 15 min (F). Phosphorylated K-Ras was detected as described in the legend to panel D. The graph
shows the mean phospho-K-Ras levels SEM from three independent experiments, with representative blots being shown. EC50, 50% effective concentration.
Significant differences between cGMP-treated and control (PBS-treated) cells were assessed using one-way ANOVA tests (*, P  0.05; **, P  0.01; ***, P 
0.001).
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K-Ras (Fig. 6B). To determine the consequences of acute PKG-
mediated K-Ras phosphorylation on signal output, MDCK cells
stably expressing K-RasG12V or K-RasG12V S181A were treated
with 8-Br-cGMP for various time intervals, and the levels of
diphosphorylated ERK (ppERK) and phosphorylated Akt (pAkt;
S473) were measured using immunoblotting. The results show
that PKGactivation acutely but transiently enhancedERKandAkt
activation inK-RasG12V-expressing cells but had aminimal effect
on cells expressing K-RasG12V S181A (Fig. 6C and D). We con-
clude that this signaling profile represents an integration of en-
hanced signal output from phospho–K-Ras nanoclusters at early
time points, which is mitigated at later time points as phosphory-
lated K-Ras is progressively lost from the PM.
Phosphorylation does not immediately dissociate K-Ras
from the PM. We next examined in more detail the kinetics of
K-RasG12V phosphorylation in situ on the PM after PKG activa-
tion in BHK cells. We first monitored mGFP-PKG2 recruitment
to the PM using EM of intact PM sheets. PKG2 recruitment to the
PM after 8-Br-cGMP treatment was rapid with a calculated half-
life (t1/2) of 8.6 min (Fig. 7A). Next, intact PM sheets from cells
expressing mGFP–K-RasG12V S181D and mCherry–K-RasG12V
were prepared after treatment with 8-Br-cGMP, and colocaliza-
FIG 3 PKG2 phosphorylates K-Ras. (A and B) Intact basal PM sheets fromMDCK cells coexpressingmGFP-PKG1 ormGFP-PKG2 andmCherry–K-RasG12V
(A) or mCherry-H-RasG12V (B) were treated with 100M8-Br-cGMP for 15min, labeled with anti-GFP–6-nm gold and anti-RFP–2-nm gold, and imaged by
EM. Spatial analyses performed using bivariate K-functions [Lbiv(r)
 r] that determine whether one gold population is clustered with respect to the other are
shown as LBI values (mean SEM), where LBI is a defined integral of the cognate Lbiv(r)
 r curve. Significant differences between bivariate K-functions for
8-Br-cGMP-treated and control (PBS-treated) cells were evaluated in bootstrap tests (***, P 0.001; N.S., not significant). (C) Intact PM sheets from MDCK
cells expressing PKG2-mGFP and treated with 100 M 8-Br-cGMP for 6 h were labeled with anti-GFP–4.5-nm gold. PM recruitment was assayed as the mean
number of gold particles per square micrometer  SEM (n  20). Significant differences between 8-Br-cGMP-treated and control (PBS-treated) cells were
evaluated in two-tailed t tests (***, P  0.001). (D) BHK cells expressing PKG2-mGFP treated with 500 M 8-Br-cGMP for 15 min were fixed with 4%
paraformaldehyde and imaged using a confocal microscope. Arrows, enhanced PKG2 recruitment to the PM. (E) cDNA from MDCK cells stably expressing
mGFP–K-RasG12V after transfectionwith PKG2-targeting siRNAor scrambled siRNAwas amplifiedwith primers specific for PKG2 exons 14 and 15 orGAPDH
exons 2 and 3. PCR products were resolved by electrophoresis and visualized by ethidium bromide staining. Images representative of those from three
independent experiments are shown. (F) MDCK cells stably expressing mGFP–K-RasG12V and transfected with scrambled or PKG2-targeting siRNA were
treated with 500M8-Br-cGMP for 15 min or 1Mbryostatin-1 (BR) for 5 min. Phosphorylated K-Ras was detected as described in the legend to Fig. 2D. The
graph shows themeanphospho-K-Ras levels SEM from three independent experiments, with representative blots being shown. Significant differences between
control and drug-treated cells were assessed using one-way ANOVA tests (*, P 0.05; **, P 0.01; ***, P 0.001; N.S., not significant). (G)MDCK cells stably
expressing mGFP–K-RasG12V and transfected with scrambled or PKG2-targeting siRNA were treated with 500 M 8-Br-cGMP for 15 min or left untreated.
PKG2 was ectopically expressed where indicated. Phosphorylated K-Ras was detected as described in the legend to Fig. 2D. The graph shows the mean
phospho-K-Ras levels SEM from three independent experiments, with representative blots being shown. Significant differences from the control (untreated
cells without PKG2 knockdown) were assessed using one-way ANOVA tests (*, P 0.05; ***, P 0.001; N.S., not significant). (H)MDCK cells stably expressing
mGFP–K-RasG12V and transfected with scrambled or PKG2-targeting siRNA were treated with 5 mM AICAR (AIC) or 0.5 M oligomycin A (O.A) for 6 h.
Phosphorylated K-Ras was detected as described in the legend to Fig. 2D. The graph shows the mean phospho-K-Ras levels  SEM from three independent
experiments, with representative blots being shown. Significant differences between control (vehicle-treated) cells and drug-treated cells were assessed using
one-way ANOVA tests (*, P 0.05; N.S., not significant).
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tion of K-RasG12V S181D and K-RasG12V was analyzed using
bivariate EM. These data show that within 15 min of PKG activa-
tion, K-RasG12V is maximally phosphorylated, as indicated by an
LBI value equal to that for the positive control; the calculated t1/2
for the LBI increase—and, hence, the inferred rate of K-Ras phos-
phorylation—was 10.1 min (Fig. 7B). This matches the time
course of PKG2 recruitment and the time scale of K-Ras phos-
phorylation measured directly by immunoblotting. In contrast,
the actual loss of K-RasG12V from the PM, again measured by
EM, was much slower with a calculated t1/2 of 37.9 min (Fig. 7C).
These data suggest that whereas activated PKG2 is rapidly re-
cruited to the PM and quantitatively phosphorylates K-RasG12V,
phosphorylation does not directly trigger the dissociation of K-
Ras from the PM.
This somewhat surprising result prompted us to directly exam-
ine the PM interactions of phosphorylated K-Ras. To this end, we
used a computational approach that provides atomistic informa-
tion on the structure and dynamics of K-Ras–membrane com-
plexes (31, 43–46). We simulated the minimal membrane-target-
ing motif of K-Ras (tK) with and without phosphorylation at
Ser181 bound to a phospholipid bilayer containing 20% PtdSer.
To directly check if phosphorylation induces spontaneous mem-
brane dissociation, we added the phosphate on Ser181 after the
peptide was already inserted into and equilibrated in the bilayer.
For better statistics, we included four peptides per system and ran
each simulation for 1 s. The starting structures for the simula-
tions were from a previous wild-type tK simulation (43), and the
simulation details are described in reference 31. Analysis of the
trajectories showed that neither phospho-tK nor tK dissociated
from the bilayer during the entire simulation length, suggesting
that phosphorylation does not dislodge K-Ras from the mem-
brane. For example, Fig. 7D shows the time evolution of the aver-
age z-position of the C- atom of the farnesylated cysteine of
phospho-tK as well as the z-position of the phosphate moiety of
the lipids that is centered to zero (i.e., a negative value indicates
insertion). It is clear fromFig. 7D that phospho-tK remains deeply
inserted in the bilayer during the entire simulation. In fact, the C
terminus of phospho-tK inserts slightly deeper into the bilayer
core than wild-type tK (Fig. 7D and E).
PKG signaling inhibits the growth of K-Ras-positive non-
small cell lung cancer cells. In K-Ras-positive cancer cells, pro-
longed activation of the AMPK¡ eNOS¡ PKG pathway phos-
phorylates oncogenic K-Ras, displaces it from the PM, and hence,
reduces oncogenic K-Ras signaling and K-Ras-dependent cell
growth. Since elements of this pathway are variably expressed, we
monitored the Ser238 phosphorylation of vasodilator-stimulated
phosphoprotein (VASP), a ubiquitously expressed PKG substrate
(47), as an assay of PKG activity (48–50). A set of K-Ras-positive
NSCLC cell lines was treated with metformin, oligomycin A,
DEA-NO, sildenafil, or 8-Br-cGMP, and phospho-VASP levels
were measured using immunoblotting. MDCK cells were used
as a control cell line. In the MDCK and H441 cell lines, all the
PKG activators increased phospho-VASP levels, whereas only
DEA-NO and 8-Br-cGMP stimulated VASP phosphorylation in
the H358 cell line (Fig. 8A and B). There were no detectable re-
sponses in the A549 and H2122 cell lines. These data suggest that
all elements of the AMPK¡ eNOS¡ sGC¡ PKG pathway are
intact in the MDCK and H441 cell lines, whereas only the lower
segment of sGC¡ PKG is present in the H358 cell line and the
pathway is not present at all in the A549 and H2122 cell lines. We
FIG 4 Activation of AMPK signaling induces K-Ras displacement from the PM. (A) The AMPK¡ PKG signaling pathway leading to K-Ras phosphorylation,
with activators indicated in blue and inhibitors indicated in red. (B)MDCK cells stably coexpressingmGFP–K-RasG12V andmCherry-CAAXwere treated with
0.5Moligomycin A, 100M8-Br-cGMP, or 100 nM sildenafil in the presence (dotted line) or absence (solid line) of 1mM L-NAME for 4 and 6 h. K-RasG12V
PM dissociation was quantified using Manders coefficients from three independent experiments. Significant difference between drug-treated and control
(vehicle-treated) cells were assessed using one-way ANOVA tests (N.S., not significant; **, P 0.01; ***, P 0.001).
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next performed cell proliferation assays. Consistent with the in-
tegrity of the PKG signaling pathway data, all PKG activators in-
hibited the proliferation of H441 cells, only DEA-NO and 8-Br-
cGMP inhibited the proliferation of H358 cells, and the A549 and
H2122 cell lines were not sensitive to any PKG activator.
DISCUSSION
In this study, we identified PKG2 to be a novel K-Ras kinase that
phosphorylates K-Ras at Ser181 in response to activation of
AMPK. PKG is activated by the AMPK-mediated activation of
eNOS, which generates cGMP through NO activation of soluble
guanylyl cyclase. Usingmultiple activators of this pathway to drive
K-Ras phosphorylation, we identified two separate consequences
of K-Ras phosphorylation. Phospho-K-RasG12V laterally segre-
gates from nonphospho-K-RasG12V to form nanoclusters that
acutely retune the K-Ras signal output to enhance both phospha-
tidylinositol 3-kinase–Akt and Raf-MAPK activation. This is mit-
igated, however, by a progressive loss of phosphorylated K-Ras
from the PM, which subsequently abrogates K-Ras signaling.
Thus, AMPK activation can both retune K-Ras signaling and si-
lence it.
The identification of PKG2 among the three expressed iso-
forms of PKG as the K-Ras kinase is based on several observations.
First, knockdownof PKG2 expressionwas sufficient to completely
abolish AMPK-mediated K-Ras phosphorylation. Second, EM ex-
periments showed that acute activation of PKG2 but no other
PKG isoform resulted in stable recruitment to K-Ras PM nano-
clusters. Third, the time course of PKG2 recruitment to the PM
closely matched that of K-Ras phosphorylation, with both pro-
cesses occurring at rates with t1/2s of 8 to 10 min. Finally, alone
among the PKG isoforms, PKG2 is N-myristoylated and has an
adjacent positively charged sequence that, likeK-Ras,may provide
additional PM affinity; cGMP activation of PKG2 appears to in-
crease PM affinity, presumably by enhancing the display of the
N-terminal lipid anchor. Little is known about the mechanism of
PKG2 PM recruitment. A recent study showed that PKG2 inter-
acts with Rab11 (51), which would potentially target PKG2 to the
recycling endosome, a distribution consistent with the confocal
imaging shown in Fig. 3D. In the context of the current study, it is
therefore possible that PKG recruitment is mediated by forward
vesicular trafficking from the recycling endosome, with cGMP-
activated PKG2 then being trapped on the PM as a result of in-
creased PM affinity.
The identification of PKG2 as a K-Ras kinase with its attendant
agonists allowed us to investigate the mechanism of K-Ras loss
from the PM. Surprisingly, displacement of K-Ras from the PM
did not occur immediately after phosphorylation; the process had
amuch longer t1/2 of 37.9min. Thus, adding one phosphate group
conferring a negative charge to the K-Ras polybasic domain at
Ser181 was not sufficient to disrupt the electrostatic interaction
between K-Ras and the PM, or else PM loss would have been
concordant with phosphorylation. This was validated byMD sim-
ulations, which showed that phosphorylation of the K-Ras poly-
basic domain, if K-Ras is already bound to a PtdSer-containing
membrane bilayer, does not trigger displacement. Indeed, phos-
phorylation results in deeper insertion of the phosphorylated an-
chor into the membrane bilayer. Therefore, we need to consider
an alternative scenariowhereby phosphorylatedK-Ras is removed
from the PM.
In this context, it has recently been shown that K-Ras is actively
FIG 5 Activation of AMPK signaling phosphorylates K-Ras. MDCK cells stably expressing mGFP–K-RasG12V were treated with 5 mM AICAR, 5 mM
metformin, or 0.5MoligomycinA for the indicated times, and cell lysates were immunoblotted for phospho-AMPK (pAMPK; T172), phospho-eNOS (peNOS;
S1177), phospho-MARKCS (pMARCKS), and phosphorylated K-Ras as described in the legend to Fig. 1D. (A) The graphs show the mean phosphorylated
AMPK, eNOS, and K-Ras levels  SEM from three independent experiments. Significant differences between control (vehicle-treated) cells and drug-treated
cells were assessed using a one-way ANOVA test (*, P 0.05; **, P 0.01; ***, P 0.001). (B) Representative blots are shown, with actin and GFP blots being
used as loading controls (top and bottom, respectively).
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maintained on the PM by an elegant spatial organizing system
(11). In brief, K-Ras removed from the PM by endocytosis is de-
livered to the cytosol because endosomes rapidly lose PtdSer
asymmetry after internalization (52). Soluble K-Ras is captured by
PDE, which unloads K-Ras in the perinuclear region in response
to Arl2/3 binding, whence K-Ras binds to the recycling endosome
(RE) for redelivery to the PM by vesicular transport (10, 11) (Fig.
9A). The rate of PM loss of K-RasG12V after phosphorylation
(t1/2  37.9 min) is consistent with the time scale of endosomal
recycling (53).We therefore propose that when PKG2 is activated,
it is recruited to the PM and phosphorylates K-Ras. Phosphory-
lated K-Ras is delivered to the cytosol by the same process by
which nonphosphorylated K-Ras is delivered and interacts nor-
mally with PDE, since binding is solely mediated through the
farnesyl group (54); it is then released by Arl2/3 at the recycling
endosome. At this point, phosphorylated K-Ras in solution must
rebind to the negatively charged REmembrane; a recentMD sim-
ulation study showed that the prenyl anchor of K-Ras phosphor-
FIG 6 K-Ras phosphorylation differentially regulates PM interactions. (A) Intact PM sheets prepared fromMDCK cells coexpressing mGFP–K-RasG12V
S181D and mCherry–K-RasG12V (solid line) or mRFP–K-RasG12V S181A (dotted line) after 8-Br-cGMP treatment for 6 h were labeled with anti-GFP–
6-nm gold and anti-RFP–2-nm gold, respectively. The extent of coclustering of the two proteins was analyzed using bivariate K-functions, shown as the
summary statistic LBI. The graph shows the mean LBI values  SEM from 20 sheets for each data point. The LBI value for coclustering of mGFP–K-
RasG12V with mCherry–K-RasG12V was measured to be 355, which implies that 500 M 8-Br-cGMP induces the nearly complete overlap of the
mGFP–K-RasG12V S181D and mCherry–K-RasG12V gold populations, consistent with 100% mCherry–K-RasG12V phosphorylation. (B) Intact PM
sheets fromMDCK cells expressing mGFP–K-RasG12V were treated for 6 h with 8-Br-cGMP, labeled with anti-GFP–4.5-nm gold, and visualized by EM.
Spatial organization was analyzed at each 8-Br-cGMP concentration using the pair correlation function g(r) (r 8 nm; data are means SEMs for 20 PM
sheets). (C and D) MDCK cells stably expressing mGFP–K-RasG12V (wild type [WT]) or mGFP–K-RasG12V S181A (S181A) were serum starved
overnight and treated with 100 M 8-Br-cGMP for various time intervals in the absence of serum. Cell lysates were quantitatively immunoblotted for
ppERK or pAkt (S473). The graphs shows the means SEMs from three independent experiments (C), with representative blots being shown (D). Total
ERK, total Akt, and GFP blots were included as loading controls.
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ylated on Ser181 is unable to efficiently insert into an ionic phos-
pholipid bilayer because of electrostatic repulsion (55). Thus,
although K-Ras, when phosphorylated while bound to a Ptd-
Ser-containing membrane, does not dissociate, soluble phos-
phorylated K-Ras is unable to rebind to such a membrane and
thus accumulates in the cytosol. In the context of the intact cell,
compromised rebinding to the recycling endosome abrogates
phosphorylated K-Ras forward transport to the PM, leading to
progressive redistribution to the cytosol and endomembrane
(Fig. 9B).
Previous work has shown that the use of ionomycin in combi-
nation with bryostatin to robustly activate PKC also mislocalizes
K-Ras from the PM (39). Under these conditions, K-Ras is lost
from the PMmuch more rapidly than it is after PKG2 activation.
However, since PKC, unlike PKG2, is able to efficiently phosphor-
ylate K-Ras on both Ser171 and Ser181, the presence of multiple
phosphate groups may cause the loss of K-Ras directly from the
PM. It is also possible that activated PKC has more extensive ac-
cess to K-Ras in multiple cellular compartments than just the K-
Ras on the PM. Calcium fluxes induced by ionomycin also acutely
reduce the electrostatic potential of the PM and separately cause
K-Ras displacement (4). Interestingly, we observed that PKC-me-
diated phosphorylation was partially abrogated after PKG2
knockdown. Taken together with previous observations that
PKC can directly activate eNOS (56), it is possible that, in addi-
tion to directly phosphorylating K-Ras, PKC also indirectly acti-
vates another K-Ras kinase, PKG2.
Two studies have shown that PKC activators can suppress the
growth of K-Ras tumors in nudemice by stimulating K-Ras phos-
phorylation (39, 57). Similarly and consistent with the loss of
phosphorylated K-Ras from the PM as a result of prolonged acti-
vation of PKG, we observed inhibition of cell proliferation in K-
Ras-positive NSCLC cells upon chronic activation of the AMPK
¡ eNOS¡ sGC¡ PKG signaling pathway. Only NSCLC cells
with an intact PKG pathway were sensitive to activators of the
pathway, and the response to specific activators correlated with
which components were expressed, identifying important bio-
markers for predicting NSCLC cell responsiveness. LKB1/STK11
is a critical AMPK-activating kinase that was originally identified
to be the product of a tumor suppressor gene (58). Germ line-
inactivating mutations of LKB1 cause Peutz-Jeghers syndrome,
which results in the development of benign polyps in the gastro-
intestinal tract, mucocutaneous pigmentation (59), and a predis-
position to the development of various cancers of the lung, pan-
creas, colon, breast, small intestine, and ovary (60). Intriguingly,
oncogenicmutant K-Ras is predominantly found in these cancers,
suggesting a correlation of the oncogenic activity of these two
proteins. Correspondingly, LKB1 nonsense mutations occur in
some 30% of K-Ras-positive NSCLC cells (61, 62). Metabolic
stress in these tumors would consequently fail to activate AMPK
FIG 7 Phosphorylation at Ser181 does not directly dissociate K-Ras from the PM. (A and C) Intact PM sheets from BHK cells expressing PKG2-mGFP
(A) or mGFP–K-RasG12V (C) and treated with 500 M 8-Br-cGMP over a time course were labeled with anti-GFP–4.5-nm gold. The PM levels of each
protein were assayed as the mean number of gold particles per square micrometer  SEM (n  20 PM sheets). Values were normalized to the values at
0 min and 360 min for K-RasG12V and PKG2, respectively. (B) PM sheets from BHK cells coexpressing mGFP–K-RasG12V S181D and mCherry–K-
RasG12V and treated with 500 M 8-Br-cGMP over a time course were labeled with anti-GFP–6-nm gold and anti-RFP–2-nm gold, respectively. The
extent of coclustering was analyzed using bivariate K-functions, summarized as LBI values, and used as an estimate of the extent of phosphorylation by
calibration with a positive-control LBI value as described in the legend to Fig. 5A. Each data point is the mean for 20 PM sheets  SEM. (D) Time
evolution of the average z-position of the C- atom of the farnesylated cysteine (red) of phospho-tK and that of the phosphate group of the lipids (black),
which is centered to zero. The average for the four peptides in the system was calculated. (E) Distribution of the difference between the z-position of the
phosphate group of the bilayer and that of the C- atom of farnesylated cysteine in wild-type (WT) tK (blue) and phospho-tK (p181; red). The left-shifted
distribution of phospho-tK indicates deeper bilayer insertion.
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and inter alia also therefore fail to remove K-Ras from the PM,
thus sustaining theK-Ras signal output. Thus, the loss of the LKB1
function in K-Ras-positive cancers would potentially prevent the
downregulation of K-Ras signaling under conditions of ATP de-
pletion.
Conversely, Counter and colleagues reported that elevated
eNOS activity contributes to the development of K-Ras-driven
pancreatic ductal adenocarcinomas (PDACs) (63). Advanced
PDACs with an induced genetic deficiency of eNOS or treatment
of mice with a NOS inhibitor limited the development of prein-
vasive pancreatic lesions and somewhat extended the mouse life
span (63). It is therefore tempting to speculate that in different
FIG 8 Activators of AMPK¡ eNOS¡ PKG signaling inhibit the proliferation of NSCLC cells expressing the target pathway. (A and B) NSCLC cell lines were
treated with 5 mM metformin (Met), 0.5 M oligomycin A (OligoA), 0.1 mM DEA-NO (NO), 100 nM sildenafil (Sild), or 500 M 8-Br-cGMP (cGMP). Cell
lysates were blotted for phospho-VASP (S239) and total VASP. Representative blots from three independent experiments are shown. Actin is shown as a loading
control. MDCK cells stably expressing K-RasG12V were used as a positive-control cell line. (C) NSCLC cells were plated on a 96-well plate and treated with the
indicated activators for 4 days. Complete growthmediumwith activators was replaced every 24 h. Cell proliferation was analyzed using a CyQuant proliferation
assay kit. The graph shows themean cell proliferation SEM(n 4 experiments) relative to that for the control cells (PBS-treated cells formetformin,DEA-NO,
and 8-Br-cGMP and dimethyl sulfoxide-treated cells for sildenafil). Closed bars, pVASP levels increased after drug treatment, as described in the legend to panels
A and B. Significant differences between activator-treated and control cells were assessed using one-way ANOVA tests (*, P 0.05; **, P 0.01; ***, P 0.001).
FIG 9 A model for PKG-mediated K-Ras PM mislocalization. (A) K-Ras removed from the PM on endocytic vesicles is released to the cytosol when PtdSer
asymmetry is lost, and cytosolic PDE binds to soluble K-Ras and unloads it in the perinuclear region in response to Arl2/3 binding, whence K-Ras is translocated
to the recycling endosome (RE) for redelivery to the PM by vesicular transport (11). (B) On activation, PKG2 is recruited to the PM (t1/2  8.6 min) and
colocalizes with K-Ras, where PKG2 phosphorylates K-Ras at Ser181 (t1/2 10.1 min). Endocytosed phospho-K-Ras translocates to the RE by the same process
as nonphosphorylated K-Ras involving PDE and Arl2/3. The phosphorylated PBD significantly reduces the affinity of K-Ras for the anionic RE membrane,
resulting in inefficient forward trafficking of K-Ras to the PM and the consequent accumulation in the cytosol and on endomembranes (t1/2 37.9 min).
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cellular contexts the different outcomes from K-Ras phosphory-
lation assume different levels of importance, such that in certain
tissues, retuning of the K-Ras signal output, albeit with the atten-
dant loss of total K-Ras from the PM, may be desirable. In this
context, acute PKG activation in vascular smooth muscle cells
enhanced the MAPK signal output (64), whereas PKG activation
in small cell lung carcinoma cells inhibited epidermal growth fac-
tor-mediated MAPK stimulation (65). The inference from the
current study that the chronic loss of PKG2 signaling allows en-
hanced K-Ras signaling is supported by observations in PKG2-
null mice that develop marked crypt hyperplasia in the colonic
epithelium, while ectopic PKG2 expression in colorectal cancer
cell lines inhibits proliferation (66).
In sum we have discovered that PKG2 is a novel K-Ras kinase
that regulates K-Ras PM interactions in response to the activation
of AMPK, rendering K-Ras signaling sensitive to metabolic stress
and other signal cascades that generate NO, although to what ex-
tent PKG2-mediated suppression of K-Ras signaling contributes
to a metabolic stress response remains to be elucidated. We also
identified components of the AMPK, eNOS, and PKG pathway to
be a set of biomarkers and tractable drug targets for K-Ras-posi-
tive cancers. Thus, K-Ras tumors that express all or some compo-
nents of the AMPK ¡ PKG signaling pathway are predictably
sensitive to specific defined activators of the pathway,which opens
up interesting therapeutic options. For example, FDA-approved
metformin, used for the treatment of type II diabetesmellitus, and
sildenafil, used for the treatment of erectile dysfunction, are likely
to have efficacy in K-Ras-positive cancer cells, where these agents
activate PKG.
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